PRIMEGENE

"Benefit patients, pray for health" PrimeGene is committed to specializing in research and development of original new external medication of inflammatory-immune diseases, and offering better treatment options to more patients, to become an enterprise reassuring patients and shouldering social responsibilities... PrimeGene focuses on inflammatory-immune disease, and is committed to offering better therapy options for patients around the world... Founded in September of 2016, Beijing PrimeGene Science and Technology Co., Ltd. ("PrimeGene", Stock code: 873969.NQ) is a company engaged in clinical stage innovative drug research and development focusing on immune-inflammatory diseases, oriented by the unmet clinical needs and featured by drugs for external use.

Primary location: Beijing China